You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,918,973


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,918,973
Title:Sustained release aminopyridine composition
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Inventor(s): Blight; Andrew R. (Mahopac, NY), Cohen; Ron (Irvington, NY)
Assignee: Acorda Therapeutics, Inc. (Ardsley, NY)
Application Number:15/482,412
Patent Claims: 1. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein a single administration of said sustained release composition of 10 milligrams of 4-aminopyridine to a human provides a maximum observed plasma concentration of 4-aminopyridine in a range of 27.7.+-.9.1 ng/mL.

2. The method of claim 1, wherein said time period comprises 12 weeks.

3. The method of claim 1, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the composition to the patient.

4. The method of claim 1, wherein said sustained release composition of 10 milligrams of 4-aminopyridine is administered without a prior period of 4-aminopyridine titration, and without a subsequent period of 4-aminopyridine titration.

5. The method of claim 1, wherein the twice daily administering is administering at 12-hour intervals.

6. The method of claim 1, wherein said sustained release composition is a tablet.

7. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, wherein twice daily administration of said sustained release composition of 10 milligrams of 4-aminopyridine to a human provides a maximum observed plasma concentration of 4-aminopyridine at steady state in a range of 32.2.+-.8.9 ng/mL.

8. The method of claim 7, wherein said time period comprises 12 weeks.

9. The method of claim 7, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the composition to the patient.

10. The method of claim 7, wherein said sustained release composition of 10 milligrams of 4-aminopyridine is administered without a prior period of 4-aminopyridine titration, and without a subsequent period of 4-aminopyridine titration.

11. The method of claim 7, wherein the twice daily administering is administering at 12-hour intervals.

12. The method of claim 7, wherein said sustained release composition is a tablet.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.